Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - SANUWAVE Health, Inc. | snwv_8k.htm |
Exhibit 99.1
SANUWAVE HEALTH APPOINTS DR. TOM PRICE TO ITS BOARD OF
DIRECTORS
SUWANEE, GA, February 7, 2020 - SANUWAVE Health,
Inc. (OTCQB: SNWV) today announced the appointment of
Dr. Tom Price to its Board of Directors. Dr. Price brings over 30
years of medical practice and knowledge to SANUWAVE. Dr.
Price’s extensive experience in public service, serving the
state of Georgia in the statehouse followed by 12 years in the
House of Representatives, brings a board perspective that shall
greatly enhance the profile and value of SANUWAVE’s Board of
Directors.
“We
are delighted to welcome Dr. Price to our Board of
Directors,” said Kevin A. Richardson II, CEO and Chairman of
the Board of Directors of SANUWAVE Health, Inc. “Tom’s
experience and background will prove invaluable as a board member
as we continue to grow and expand as a company. We look forward to
his strategic insights and guidance as we navigate this rapid
growth and the challenges that come with it in the coming
years,” concluded Mr. Richardson.
Dr.
Price holds a BA and MD from the University of Michigan and
completed his residency in orthopedic surgery at Emory University
in Atlanta. He entered private practice in 1984 and returned to
Emory as an assistant professor in of orthopedic surgery in 2002.
He was director of the orthopedic clinic at Atlanta’s Grady
Memorial Hospital. Dr. Price’s political career began as a
Member of the Georgia Senate from the 56th district from 1996
to 2005, he was the minority Whip from 1998 to 2002, and the
Majority leader of the Georgia Senate from 2002 to 2003. He served
in the US House of Representatives from Georgia’s
6th
district from 2005 to 2017. During which time he served as Chair of
the House Budget Committee from 2015 to 2017. In February 2017 he
was confirmed by the Senate as the United States Secretary of
Health and Human Services (HHS) and remained in that position until
September 2017. Currently Tom serves on the boards of several
privately held health care companies and non-profits as well as,
consulting and advising companies.
Commenting
on his appointment, Dr. Price stated, “I am very excited to
join SANUWAVE’s Board of Directors at this point in time when
they are entering the commercialization phase with such rapid
growth. I am impressed with SANUWAVE’s commitment in research
and development and clinical trials to treating cumbersome medical
conditions. Diabetes afflicts millions of Americans and even more
globally. The dermaPACE System for treating Diabetic Foot Ulcers
(DFUs) is a novel and effective treatment to help improve the
quality of life for diabetic patients. I am especially impressed
and ready to assist the team achieve their goal of having a device
placed anywhere and everywhere a DFU is
treated.”
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com)
is a shockwave technology company initially focused on the
development and commercialization of patented noninvasive,
biological response activating devices for the repair and
regeneration of skin, musculoskeletal tissue and vascular
structures. SANUWAVE’s portfolio of regenerative medicine
products and product candidates activate biologic signaling and
angiogenic responses, producing new vascularization and
microcirculatory improvement, which helps restore the body’s
normal healing processes and regeneration. SANUWAVE applies its
patented PACE®
technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead
product candidate for the global wound care market,
dermaPACE®,
is US FDA cleared for the treatment of Diabetic Foot Ulcers.
The device is also CE Marked throughout Europe and has device
license approval for the treatment of the skin and subcutaneous
soft tissue in Canada, South Korea, Australia and New Zealand.
SANUWAVE researches, designs, manufactures, markets and services
its products worldwide, and believes it has demonstrated that its
technology is safe and effective in stimulating healing in chronic
conditions of the foot (plantar fasciitis) and the elbow (lateral
epicondylitis) through its U.S. Class III PMA approved
OssaTron® device,
as well as stimulating bone and chronic tendonitis regeneration in
the musculoskeletal environment through the utilization of its
OssaTron, Evotron® and
orthoPACE® devices
in Europe, Asia and Asia/Pacific. In addition, there are
license/partnership opportunities for SANUWAVE’s shockwave
technology for non-medical uses, including energy, water, food and
industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking
statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, such as statements relating to
financial results and plans for future business development
activities, and are thus prospective. Forward-looking statements
include all statements that are not statements of historical fact
regarding intent, belief or current expectations of the Company,
its directors or its officers. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are
beyond the Company’s ability to control. Actual results may
differ materially from those projected in the forward-looking
statements. Among the key risks, assumptions and factors that may
affect operating results, performance and financial condition are
risks associated with the regulatory approval and marketing of the
Company’s product candidates and products, unproven
pre-clinical and clinical development activities, regulatory
oversight, the Company’s ability to manage its capital
resource issues, competition, and the other factors discussed in
detail in the Company’s periodic filings with the Securities
and Exchange Commission. The Company undertakes no obligation to
update any forward-looking statement.
For additional information about the Company, visit
www.sanuwave.com.
Contact:
Millennium
Park Capital LLC
Christopher
Wynne
312-724-7845
cwynne@mparkcm.com
SANUWAVE
Health, Inc.
Kevin
Richardson II
CEO and
Chairman of the Board
978-922-2447
investorrelations@sanuwave.com